# PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

> **NCT04040491** · PHASE4 · UNKNOWN · sponsor: **Mingzhi Zhang** · enrollment: 100 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine

## Key facts

- **NCT ID:** NCT04040491
- **Lead sponsor:** Mingzhi Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04040491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04040491, "PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04040491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*